Targeted radioligand therapy (RLT) with Lutetium-177-prostate-specific membrane antigen ligand (177Lu-PSMA) has emerged as a new and effective treatment option in patients with metastatic castration–resistant prostate cancer (mCRPC). Here, FOLH1 is linked to prostate carcinoma.